Immunicom
Immunicom, headquartered in San Diego, CA, develops non-pharmaceutical therapies for cancer and other diseases, and has received significant regulatory approvals for its innovative Immunopheresis therapy.
Company Overview
Immunicom is a med-tech company focused on the development of non-pharmaceutical approaches to treat cancer, autoimmune disorders, and inflammatory and renal diseases. The company is headquartered in San Diego, CA, and operates additional facilities in Philadelphia, PA, Houston, TX, and Krakow, Poland.
FDA Breakthrough Device Designation
Immunicom's Immunopheresis therapy has received the FDA Breakthrough Device designation. This designation is granted to innovative medical devices that offer significant advantages over existing alternatives in treating or diagnosing life-threatening or irreversibly debilitating diseases or conditions.
European CE Mark Certification
The LW-02 blood-filtering immunotherapy device developed by Immunicom has earned the European CE Mark Certification. This certification verifies that the device meets EU safety, health, and environmental protection requirements. The LW-02 is intended for use in adults with advanced, refractory, triple-negative breast cancer.
Clinical Trials
Immunicom is actively conducting clinical trials globally to evaluate the efficacy of its Immunopheresis therapy across various cancer types. These trials are being carried out in collaboration with leading hospitals and research institutions around the world.
Immunopheresis Therapy
Immunopheresis is a therapeutic device developed by Immunicom for treating cancer. The device operates outside of the body and is designed to remove specific immune-suppressive cytokines produced by cancer tumors from the blood, thereby enabling the immune system to better attack the cancer.